Enhancing outcomes from major depression: Using antidepressant combination therapies with multifunctional pharmacologic mechanisms from the initiation of treatment

CNS Spectrums

Volumn 15, Issue 2, 2010, Pages 79-94

  Stahl, Stephen M ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AGOMELATINE; AMFEBUTAMONE; ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; BUSPIRONE; DOXEPIN; DULOXETINE; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; FOLIC ACID; FOLIC ACID DERIVATIVE; FOLINIC ACID; HYPNOTIC AGENT; LEVO METHYLFOLATE; LITHIUM; MIRTAZAPINE; MONOAMINE OXIDASE INHIBITOR; OMEGA 3 FATTY ACID; PAROXETINE; QUETIAPINE; REBOXETINE; S ADENOSYLMETHIONINE; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRAZODONE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VENLAFAXINE;

CLINICAL TRIAL; DRUG ANTAGONISM; DRUG BLOOD LEVEL; DRUG COST; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG TOLERABILITY; EPIGENETICS; HUMAN; HYPERICUM PERFORATUM; LOW DRUG DOSE; MAJOR DEPRESSION; PHARMACOGENOMICS; PRIORITY JOURNAL; PSYCHOPHARMACOLOGY; REMISSION; REVIEW; SEDATION; SIDE EFFECT; UNSPECIFIED SIDE EFFECT;

EID: 77949281906     PISSN: 10928529     EISSN: None     Source Type: Journal    
DOI: 10.1017/S1092852900027334     Document Type: Review

References (55)

1. American Psychiatric Association, Practice Guidelines for Major depressive disorder, second edition, 2005, DOI: 10.1176/appi.books. 9780890423363.48690
2. Stahl SM. Stahls Essential Psychopharmacocology, 3rd edition. New York, NY: Cambridge University Press; 2008.
3. Rush AJ, Trivedi MH, Wisniewski SR, et al. Acute and longer term outcomes in depressed outpatients requiring one or several treatment steps: A Star*D report. Am J Psychiatry. 2006;163:1905-1917.
4. Warden D, Rush AJ, Trivedi MH, Fava M, Wisneiwski SR. The STAR*D project results: a comprehensive review of findings. Curr Psychiatry Rep. 2007;9:449-459.
5. Cipriani A, Furukawa TA, Salanti G, et al. Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta analysis. Lancet. 2009;373:746-758.
6. Stahl SM. Multifunctional Drugs: A Novel Concept for Psychopharmacology. CNS Spectr. 2008;14:71-73.
7. Millan M. Dual and triple acting agents for treating core and comorbid symptoms of major depression: novel concepts, new drugs. Neurotherapeutics 2009;6:53-77.
8. Stahl SM. Combining antidepressant therapies from the initiation of treatment: a paradigm shift for major depression. J Clin Psychiatry. 2009;70:1493-1494.
9. Brunton LL. Goodman and Gilman's The Pharmacological Basis of Therapeutics, 11th edition. New York, NY: McGraw Hill; 2006.
10. Stahl SM. Stahls Essential Psychopharmacology Prescriber's Guide. New York, NY: Cambridge University Press ;2009.
11. Fava M, Rush AJ. Current Status of Augmentation and Combination Treatments for Major Depressive Disorder: A literature review and a proposal for a novel approach to improve practice. Psychother Psychosom. 2006;75:139-153.
12. Freeman M, Fava M, Mischoulon D, Papakostas G, Shelton R. The use of complimentary and alternative medicines to achieve remission in major depressive disorder. J Clin Psychiatry. 2009;70 (suppl 5): 1-27.
13. Stahl SM. Novel therapeutics for depression: L-methylfolate (6 (S)-5-methyltetrahydrofolate or MTHF) as a trimonoamine modulator and antidepressant augmenting agent. CNS Spectr. 2007;12:423-428.
14. Pan C-C, McQuoid DR, Taylor WD, Payne ME, Ashley-Koch A, Staffens DC. Association analysis of the COMT/MTHFR genes and geriatric depression: an MRI study of the putamen. Int J Geriatr Psychiatry. 2009;24:847-855.
15. Lewis SJ, Lawlor DA, Davey Smith G, et al. The thermolabile variant of MTHFR is associated with depression in the British Women's heart and health study and a meta analysis. Mol Psychiatry. 2006;11: 352-360.
16. Kelly CB, McDonnell AP, Johnston TG, et al. The MTHFR C677T polymorphism is associated with depressive episodes in patients from Northern Ireland. J Psychopharmacol. 2004;18: 567-571.
17. Ariami T, Yamada N, Yamakawa-Kobayashi K. Methylenetetrahydrofolate reductase variant and schizophrenia/depression. Am J Med Genet. 1997;74: 526-528.
18. Gilbody S, Lewis S, Lightfoot T. Methylenetetrahydrofolate reductase genetic polymorphisms and psychiatric disorders: A Huge review. Am J Epidemiol. 2007;165:1-13.
19. Stahl SM. L-methylfolate: a vitamin for your monoamines. J Clin Psychiatry. 2008;69:1352-1353.
20. Delgado PL, Miller HL, Salomon RM. Tryptophan-depletion in depressed patients treated with desipramine or fluoxetine: implications for the role of serotonin in the mechanism of antidepressant action. Biol Psychiatr. 199;46:212-220
21. Godfrey PS, Toone BK, Carney MWB, et al. Enhancement of recovery from psychiatric illness by methylfolate. Lancet. 1990;336:392-395.
22. Coppen A, Bailey J. Enhancement of the antidepressant action of fluoxetine by folic acid: a randomized, placebo controlled trial. J Affective Dis. 2000;60:121-130.
23. Resler G, Lavie R, Campos J, et al. Effect of folic acid combined with fluxetine in patients with major depression on plasma homocysteine and vitamin B12, and serotonin levels in lymphocytes. Neuroimmunomodulation. 2008;15:145-152.
24. Bottiglieri T. Homocysteine and folate metabolism in depression. Prog Neuropsychopharmacol Biol Psychiatry. 2005;29:1103-1112.
25. Stahl SM. Personalized Medicine, Pharmacogenomics, and the Practice of Psychiatry: On the Threshold of Predictive Therapeutics in Psychopharmacology? CNS Spectr. 2008;13:115-118.
26. Stahl SM. Epigenetics and methylomics in psychiatry. J Clin Psychiatry. 2009;70:1204-1205.
27. Massat I, Sourey D, Del-Favero J, et al. Association between COMT (Val 148 Met) functional polymorphism and early onset in patients with major depressive disorder in a European multicenter genetic association study. Mol Psychiatry. 2005;10:598-605.
28. Baune BT, Hohoff Ch, Berger K, et al. Association of the COMT val 58 met variant with antidepressant treatment response in major depression. Neuropsychopharmacol. 2008;33:924-932.
29. Yoshida K, Higuchi H, Takahashi H, et al. Influence of the tyrosine hydroxylase val81met polymorphism and catechol-O-methyltransferase val 155 met polymorphism on the antidepressant effect of milnacipran. Human Psychopharmacol. 2008;23:121-128.
30. Benedetti F, Colombo C, Pirovano A, Marino E, Smeraldi E. The catechol-O-methyltransferase Val(108/158)Met polymorphism affects antidepressant response to paroxetine in a naturalistic setting. Psychopharmacology (Berl). 2009;203:155-160.
31. Tsai SJ, Gau YT, Hong CJ, Liou YJ, Yu YW, Chen TJ. Sexually dimorphic effect of catechol-O-methyltransferase val158met polymorphism on clinical response to fluoxetine in major depressive patients. J Affect Disord. 2009;113:183-187.
32. Arias B, Serretti A, Lorenzi C, Gastó C, Catalán R, Fañanás L. Analysis of COMT gene (Val 158 Met polymorphism) in the clinical response to SSRIs in depressive patients of European origin. J Affect Disord. 2006;90:251-256.
33. Funke B, Malhotra AK, Finn CT, et al. COMT genetic variation confers risk for psychotic and affective disorders: a case control study. Behav Brain Funct. 2005;1:19.
34. Szegedi A, Rujescu D, Tadic A, et al. The catechol-O-methyltransferase Val108/158Met polymorphism affects short-term treatment response to mirtazapine, but not to paroxetine in major depression. Pharmacogenomics J. 2005;5:49-53.
35. Potter GG, Taylor WD, McQuoid DR, Steffens DC, Welsh-Bohmer KA, Krishnan KR. The COMT Val158Met polymorphism and cognition in depressed and nondepressed older adults. Int J Geriatr Psychiatry. 2009 ;24:1127-1133.
36. Zalsman G, Huang YY, Oquendo MA, et al. No association of COMT Val158Met polymorphism with suicidal behavior or CSF monoamine metabolites in mood disorders. Arch Suicide Res. 2008;12:327-335.
37. Baekken PM, Skorpen F, Stordal E, Zwart JA, Hagen K. Depression and anxiety in relation to catechol-O-methyltransferase Val158Met genotype in the general population: the Nord-Trøndelag Health Study (HUNT). BMC Psychiatry. 2008;8:48.
38. Tunbridge EM, Harrison PJ, Warden DR, Johnston C, Refsum H, Smith AD. Polymorphisms in the catechol-O-methyltransferase (COMT) gene influence plasma total homocysteine levels. Am J Med Genet B Neuropsychiatr Genet. 2008;147B:996-999.
39. Nestler EJ. Epigenetic mechanisms in psychiatry. Biol Psychiatry. 2009;65:189-190.
40. Jiang Y, Sun T, Xiong J, Cao J, Li G, Want S. Hyperhomocysteinemia- mediated DNA hypmethylation and its potential epigenetic role in rats. Acta Biochimica et Biophysica Sinica. 2007;39:657-667.
41. Sasaki M, Kaneuchi M, Sakuragi N, Dahiya R. Multiple promoters of catechol-Omethyltransferase gene are selectively inactivated by CpG hypermethylation in endometrial cancer. Cancer Res. 2003;63:3101-3106.
42. Abdolmaleky HM, Cheng KH, Faraone SV, et al. Hypomethylation of MB-COMT promoter is a major risk factor for schizophrenia and bipolar disorder. Hum Mol Genet. 2006;15:3132-3145.
43. Mill J, Dempster E, Caspi A, Williams B, Moffitt T, Craig I. Evidence for monozygotic twin (MZ) discordance in methylation level at two CpG sites in the promoter region of the catechol-O-methyltransferase (COMT) gene. Am J Med Genet B Neuropsychiatr Genet. 2006;141B:421-425.
44. Nierenberg A, Bronwyn RK, Leslie VC, et al. Residual symptoms in depressed patients who respond acutely to fluoxetine. J Clin Psychiatry. 1999;60:221-225.
45. Stahl SM. Selective Histamine H1 Antagonism: Novel Hypnotic and Pharmacologic Actions Challenge Classical Notions of Antihistamines. CNS Spectr. 2008;13:1027-1038.
46. Stahl SM. Mechanism of action of trazodone, a multifunctional drug. CNS Spectr. 2009;14:536-546.
47. Stahl SM, Fava M, Trivedi M,Caputo A, Shah A, Post A. Agomelatine in the Treatment of Major Depressive Disorder: An 8 week, Multicenter, Randomized, Placebo-controlled Trial. Journal of Clinical Psychiatry. In press.
48. Fava M, Asnis GM, Shrivastava R, et al. Zolpidem extended-release improves sleep and next-day symptoms in comorbid insomnia and generalized anxiety disorder. J Clin Psychopharmacol. 2009;29:222-230.
49. Pollack, M, Kinrys G, Krystal A, et al. Eszopiclone coadministered with escitalopram in patients with insomnia and comorbid generalized anxiety disorder. Arch Gen Psychiatry. 2008;65:551-562.
50. Nutt D, Stahl SM. Searching for perfect sleep: the continuing evolution of GABAA receptor modulators as hypnotics. Journal of Psychopharmacology. In press.
51. Fava M, McCall Krystal A, Wessel T, et al. Eszopiclone co-administered with fluoxetine in patients with insomnia coexisting with major depressive disorder. Biol Psychiatry. 2006;59:1052-1060.
52. Nelson JC, Mazure CM, Jatlow PI, Bowers MB, Price LH, Combining norepinephrine and serotonin reuptake inhibition mechanism for treatment of depression: a double-blind, randomized study. Biol Psychiatry. 2004;55:296-300.
53. Blier P, Gobbi G, Turcotte JE, et al. Mirtazapine and paroxetine in major depression: a comparison of monotherapy versus their combination from treatment initiation. Eur Neuropsychopharmacol. 2009;19:457-465.
54. Blier P, Ward HE, Tremblay P, Laberge L, Hebert C, Bergeron R. Combination of antidepressant medications from treatment initiation for major depressive disorder: a double blind randomized study. Am J Psychiatry. Epub ahead of print.
55. Bares M, Novak T, Kopecek M, Kopecek M, Stopkova P, Sos P. Is combined treatment more effective than switching to monotherapy in patients with resistant depression? A retrospective study. Neuro Endocrinol Lett. Dec 30, 2009. Epub ahead of print.